Ranibizumab

Indication

Red

Brand:

Lucentis®

Nice TA:

283

Commissioning responsibility:

CCG

PbR excluded:

Yes

BNF chapter:

Eye

1.1 Ranibizumab is recommended as an option for treating visual impairment caused by macular oedema:

following central retinal vein occlusion or
following branch retinal vein occlusion only if treatment with laser photocoagulation has not been beneficial, or when laser photocoagulation is not suitable because of the extent of macular haemorrhage and
only if the manufacturers of ranibizumab (branded or biosimilar) provide it at a discount level no lower than the discount agreed in the patient access scheme.

LSCMMG Recommendation:

Red

Reason for decision:

Specialist medicine

Supporting documents:

BwD	BP	CSR	EL	FW	GP	MB	WL
Pending	Red	Red	Pending	Red	Red	Red	Red

What do the colours mean?

Last Updated: 16 - Oct - 2019